AU4925290A - Pharmaceutical compositions comprising cyclosporin and a fatty acid saccharide monoester - Google Patents

Pharmaceutical compositions comprising cyclosporin and a fatty acid saccharide monoester

Info

Publication number
AU4925290A
AU4925290A AU49252/90A AU4925290A AU4925290A AU 4925290 A AU4925290 A AU 4925290A AU 49252/90 A AU49252/90 A AU 49252/90A AU 4925290 A AU4925290 A AU 4925290A AU 4925290 A AU4925290 A AU 4925290A
Authority
AU
Australia
Prior art keywords
cyclosporin
fatty acid
pharmaceutical compositions
acid saccharide
saccharide monoester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU49252/90A
Other versions
AU630413B2 (en
Inventor
Birgit Hauer
Ulrich Posanski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898902898A external-priority patent/GB8902898D0/en
Priority claimed from GB898902901A external-priority patent/GB8902901D0/en
Priority claimed from GB898903147A external-priority patent/GB8903147D0/en
Priority claimed from GB898903663A external-priority patent/GB8903663D0/en
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU4925290A publication Critical patent/AU4925290A/en
Application granted granted Critical
Publication of AU630413B2 publication Critical patent/AU630413B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: SANDOZ LTD.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
AU49252/90A 1989-02-09 1990-02-08 Pharmaceutical compositions comprising cyclosporin and a fatty acid saccharide monoester Expired AU630413B2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB8902898 1989-02-09
GB898902898A GB8902898D0 (en) 1989-02-09 1989-02-09 Improvements in or relating to organic compounds
GB8902901 1989-02-09
GB898902901A GB8902901D0 (en) 1989-02-09 1989-02-09 Improvements in or relating to organic compounds
GB8903147 1989-02-13
GB898903147A GB8903147D0 (en) 1989-02-13 1989-02-13 Improvements in or relating to organic compounds
GB898903663A GB8903663D0 (en) 1989-02-17 1989-02-17 Improvements in or relating to organic compounds
GB8903663 1989-02-17

Publications (2)

Publication Number Publication Date
AU4925290A true AU4925290A (en) 1990-08-16
AU630413B2 AU630413B2 (en) 1992-10-29

Family

ID=27450262

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49252/90A Expired AU630413B2 (en) 1989-02-09 1990-02-08 Pharmaceutical compositions comprising cyclosporin and a fatty acid saccharide monoester

Country Status (25)

Country Link
JP (3) JP3484190B2 (en)
KR (1) KR0170769B1 (en)
AT (1) AT404552B (en)
AU (1) AU630413B2 (en)
BE (1) BE1003009A5 (en)
CA (1) CA2009533C (en)
CH (1) CH679277A5 (en)
CY (1) CY1903A (en)
DE (1) DE4003844B4 (en)
DK (1) DK176209B1 (en)
ES (1) ES2021942A6 (en)
FI (1) FI97524C (en)
FR (1) FR2642650B1 (en)
GB (1) GB2230440B (en)
HK (1) HK37296A (en)
HU (1) HU213394B (en)
IT (1) IT1240758B (en)
LU (1) LU87675A1 (en)
MY (1) MY107377A (en)
NL (1) NL195028C (en)
NO (1) NO301576B1 (en)
NZ (1) NZ232401A (en)
PH (1) PH30917A (en)
PT (1) PT93079B (en)
SE (1) SE511398C2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627220B2 (en) * 1988-09-16 1992-08-20 Novartis Ag Improvements in or relating to organic compounds

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
MX9201782A (en) † 1991-04-19 1992-10-01 Sandoz Ag PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, SUBSTANTIALLY INSOLUBLE IN WATER, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5759566A (en) * 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
DK0589843T3 (en) 1992-09-25 2002-04-02 Novartis Ag Cyclosporin-containing pharmaceutical preparations
HUT72738A (en) * 1993-04-20 1996-05-28 Rentschler Arzneimittel New cyclosporine-containing pharmaceutical compositions for oral administration
DE4412201A1 (en) * 1993-04-20 1994-11-10 Rentschler Arzneimittel New pharmaceutical preparations for oral administration containing cyclosporin
DE4340781C3 (en) * 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
KR0146671B1 (en) * 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
CN1121238C (en) 1994-11-03 2003-09-17 诺瓦蒂斯有限公司 Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability and process for producing them
US5679566A (en) * 1995-01-20 1997-10-21 University Of Massachusetts Medical Center Yeast NMD2 gene
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
DE19544507B4 (en) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
KR20000069900A (en) * 1997-01-30 2000-11-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 Oil-Free Pharmaceutical Compositions Containing Cyclosporin A
AU762247B2 (en) * 1997-01-30 2003-06-19 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin A
HU228855B1 (en) * 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
JP4521554B2 (en) * 2004-03-31 2010-08-11 マイラン製薬株式会社 Cyclosporine preparation
CN101360485B (en) * 2005-10-26 2013-04-17 班纳制药公司 Hydrophilic vehicle-based dual controlled release matrix system
WO2007112272A2 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102008059201A1 (en) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ precipitating drug solutions
KR102146704B1 (en) 2018-04-13 2020-08-21 가천대학교 산학협력단 Cyclosporin a containing microstructures for transdermal and intradermal drug delivery
EP4166133A1 (en) * 2021-10-13 2023-04-19 Chugai Seiyaku Kabushiki Kaisha Composition containing peptide compound and surfactant

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (en) * 1978-03-07 1984-08-10 Sandoz Ag FRAMEWORK FOR PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE A
JPS61280435A (en) * 1985-04-04 1986-12-11 Kanji Takada Lymph orienting preparation of cyclosporin
NL8600050A (en) * 1986-01-13 1987-08-03 Sanico Nv PHARMACEUTICAL PREPARATION WITH DELAYED DELIVERY OF THE ACTIVE SUBSTANCE AND METHOD FOR PREPARING IT.
GB8602372D0 (en) * 1986-01-31 1986-03-05 Sandoz Ltd Organic compounds
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
EP0267615A3 (en) * 1986-11-13 1989-05-03 Sloan-Kettering Institute For Cancer Research Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2
EP0296122B1 (en) * 1987-06-17 1993-09-29 Sandoz Ag Cyclosporins and their use as pharmaceuticals
JP2536876B2 (en) * 1987-07-31 1996-09-25 寛治 高田 Dissolvable powder formulation of cyclosporine
DE3830494B4 (en) * 1987-09-15 2006-05-18 Novartis Ag Water-soluble monoesters as solubilizers for pharmacologically active substances and pharmaceutical excipients
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
HU205010B (en) * 1987-09-15 1992-03-30 Sandoz Ag Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
JP2792862B2 (en) * 1988-07-30 1998-09-03 寛治 高田 Oral enteric formulation
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
JPH1038029A (en) * 1996-07-26 1998-02-13 Ebara Corp Dick shape structure with vibration damping function
JPH10280435A (en) * 1997-04-03 1998-10-20 Sekisui Chem Co Ltd Construction method of basement

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627220B2 (en) * 1988-09-16 1992-08-20 Novartis Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
GB9002504D0 (en) 1990-04-04
DK176209B1 (en) 2007-02-05
DE4003844B4 (en) 2007-09-20
JP2001302538A (en) 2001-10-31
NO301576B1 (en) 1997-11-17
FR2642650A1 (en) 1990-08-10
JPH02235817A (en) 1990-09-18
ATA27290A (en) 1998-05-15
NL195028C (en) 2003-12-02
FI900604A0 (en) 1990-02-07
KR900012625A (en) 1990-09-01
NO900577L (en) 1990-08-10
IT9047609A0 (en) 1990-02-08
NL195028B (en) 2003-08-01
JP2006001947A (en) 2006-01-05
HU900701D0 (en) 1990-04-28
IT9047609A1 (en) 1991-08-08
FR2642650B1 (en) 1994-12-09
GB2230440B (en) 1993-05-19
CA2009533C (en) 2002-11-12
NO900577D0 (en) 1990-02-07
IT1240758B (en) 1993-12-17
JP4073641B2 (en) 2008-04-09
AU630413B2 (en) 1992-10-29
NZ232401A (en) 1992-10-28
KR0170769B1 (en) 1999-02-01
ES2021942A6 (en) 1991-11-16
SE9000441L (en) 1991-08-08
AT404552B (en) 1998-12-28
PH30917A (en) 1997-12-23
JP3484190B2 (en) 2004-01-06
PT93079A (en) 1990-08-31
PT93079B (en) 1996-04-30
MY107377A (en) 1995-11-30
SE9000441D0 (en) 1990-02-07
CA2009533A1 (en) 1990-08-09
GB2230440A (en) 1990-10-24
FI97524C (en) 1997-01-10
HK37296A (en) 1996-03-15
HU213394B (en) 1997-06-30
NL9000299A (en) 1990-09-03
DK32790D0 (en) 1990-02-07
SE511398C2 (en) 1999-09-20
CH679277A5 (en) 1992-01-31
BE1003009A5 (en) 1991-10-22
CY1903A (en) 1996-11-22
DE4003844A1 (en) 1990-08-16
DK32790A (en) 1990-08-10
FI97524B (en) 1996-09-30
LU87675A1 (en) 1991-10-08

Similar Documents

Publication Publication Date Title
AU4925290A (en) Pharmaceutical compositions comprising cyclosporin and a fatty acid saccharide monoester
AU4081489A (en) Fatty acid therapy and compositions
AU3896789A (en) Fatty acid composition
IL103932A (en) Fatty acid and pharmaceutical compositions containing them
IL91642A0 (en) Pharmaceutical compositions comprising cyclosporins
AU4341789A (en) Pharmaceutical formulations
AU638768B2 (en) Pharmaceutical and cosmetic depigmentation compositions with a caffeic acid base
NZ230631A (en) Nitrate esters and pharmaceutical compositions
IL87800A0 (en) Dioxolane-2-carboxylic acids and pharmaceutical compositions comprising them
AU5541290A (en) Pharmaceutical compositions
HUT51105A (en) Pesticide comprising substituted acrylic acid ester derivatives as active ingredient and process for producing the active ingredients
IL95994A0 (en) Carbamate esters and pharmaceutical compositions containing them
AU5252090A (en) Improvements in and relating to pharmaceutical formulations
IL85776A0 (en) Pharmaceutical compositions comprising certain algae and polyunsaturated fatty acids and their preparation
AU6012990A (en) Pharmaceutical formulation
PT75762A (en) Aminocyclopentane acids and esters and their preparation and pharmaceutical formulation
AU5276690A (en) Pharmaceutical compositions
AU1507688A (en) Pharmaceutical compositions
IL93298A0 (en) Pharmaceutical compositions comprising cyclosporin
PT86265A (en) Oleic acid esters and pharmaceutical compositions
IL93821A0 (en) Esters,their preparation and pharmaceutical compositions containing them
IL95367A0 (en) 2-fluorocyclopropylacetic acid esters and pesticidal compositions containing the same
KR100235524B1 (en) Pharmaceutical compositions comprising cyclosporins
ZA966256B (en) Novel fatty acid derivative which can be used in the preparation of a medicament
GB8918293D0 (en) Fatty acid therapy and compositions